UK-based biotech company focused on developing molecules that inhibit novel DNA damage response (DDR) targets
Nodus Oncology has raised €2.7M across 1 funding round from 2 investors, most recently a round in Feb 2023. Based in Edinburgh, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-02-07 | Other | €2.7M |
| Cumulus Oncology,KHAN Technology Transfer Fund I |
| View deal → |
